Pandemic Profiteers

[Stone]

More pandemic profiteers: COVID-19 vaccines have minted at least NINE new pharma billionaires - and their combined wealth

 is enough to buy shots for 780 MILLION people in low-income nations

• Nine executives from Moderna, BioNTech, ROVI and CanSino Biologics have all become billionaires throughout the pandemic
  
  
• Together they are now worth $19.3 billion - a combined net wealth greater than what it would cost to vaccinate the world's poorest nations
  

• The list was compiled by the People's Vaccine Alliance, a campaign group that includes Oxfam, UNAIDS, Global Justice Now and Amnesty International
  

• Moderna CEO Stéphane Bancel is now worth a whopping $4.3 billion after his company was granted emergency use authorization in the US in December
  

• CEO and co-founder of BioNTech Ugur Sahin is close behind with a wealth of $4 billion, following its collaboration on a vaccine with Pfizer
  

• Senior executives from CanSino Biologics have also become billionaires after it developed a one-shot vaccine that was approved for use in China this February 
  

• It comes as world leaders will discuss at the G20 Global Health Summit whether to waive patent protections for COVID-19 vaccines
  

• Supporters say it will allow more manufacturers to produce life-saving vaccines and increase their supply to poorer countries
  

Daily Mail |  21 May 2021

The development and rollout of COVID-19 vaccines has minted at least nine new billionaires in the pharma industry, whose new combined wealth is enough to buy shots for a staggering 780 million people in low-income nations. 

Nine executives from Moderna, BioNTech, ROVI and CanSino Biologics have hugely profited from the pandemic that has so far killed 3.4 million people worldwide, as their individual wealth soared past the billion-dollar mark over the last year.

The rich list was compiled by the People's Vaccine Alliance, a campaign group that includes Oxfam, UNAIDS, Global Justice Now and Amnesty International, using the Forbes Rich List.

Topping the list is the CEO of Moderna Stéphane Bancel who is now worth a whopping $4.3 billion after his company became the second to be granted emergency use authorization in the US for its vaccine back in December. 

CEO and co-founder of BioNTech Ugur Sahin is close behind with a wealth of $4 billion, following its collaboration on a vaccine with Pfizer.

Other Moderna execs have also profited, with immunologist and early investor Timothy Springer now worth $2.2 billion, Chairman Noubar Afeyan $1.9 billion and scientist and founding investor Robert Langer $1.6 billion.

Senior executives from CanSino Biologics have also become billionaires over the last year with the Chinese firm's co-founder and chief scientific officer Zhu Tao now worth $1.3 billion, co-founder and Senior Vice President QiuDongxu worth $1.2 billion and co-founder and Senior Vice President Mao Huinhoa $1 billion.

CanSino has developed a one-shot vaccine that was approved for use in China this February.

The ninth newfound billionaire is ROVI Chairman Juan Lopez-Belmonte, who is now worth $1.8 billion. Spanish contract drugmaker Rovi makes bottles for Moderna's vaccine and last month reached a new deal to start making its active ingredients.

Together, the industry's nine new billionaires are worth $19.3 billion.

This is a combined net wealth greater than what it would cost to vaccinate the world's poorest nations.

With the average vaccine costing $19 and 775,710,612 people living in low-income countries, according to UN data, this money would be enough to vaccinate every person 1.3 times, the alliance said.     

The alliance released its analysis to show how the pandemic has exacerbated inequities in healthcare among the rich and poor.

While the pandemic has ravaged the world, killing millions and throwing even more further into poverty, a small faction of pharma executives have made a tidy profit. 

As well as the new billionaire set, the pandemic has also seen the rich get richer. 

Eight existing billionaires with big stakes in the pharma companies behind the COVID-19 vaccines have seen their combined wealth increase by a staggering $32.2 billion, the research found.

This wealth would be enough to fully vaccinate everyone in India.

Anne Marriott, Oxfam's health policy manager, said the pharma companies and the execs behind them have taken the monopoly on the COVID-19 vaccine.

'These billionaires are the human face of the huge profits many pharmaceutical corporations are making from the monopoly they hold on these vaccines,' she said. 

'These vaccines were funded by public money and should be first and foremost a global public good, not a private profit opportunity,' she added. 

Shares in pharma companies responsible for developing the vaccines skyrocketed as they gained authorization for use in nations across the world.   

Moderna has seen its share price surge more than 700 percent since last February when COVID shuttered much of the world.

During the same timeframe, BioNTech has increased by 600 percent and CanSino Biologics 440 percent.   

The research comes ahead of the G20 Global Health Summit where world leaders are expected to discuss whether to waive patent protections for COVID-19 vaccines. 

Supporters say it will allow more manufacturers to produce life-saving vaccines and increase their supply to poorer countries.

Joe Biden has said America supports waiving intellectual property protections to allow poorer countries hard hit by the virus to produce vaccines.

However other nations such as Germany are opposed to it, saying IP rights are a source of innovation.   

There's also been pushback from some top names in pharma as such a move would likely slash their profits.

Pfizer CEO Albert Bourla blasted the idea as 'so wrong', saying it would punish the firm for its progress and discourage biotech companies from creating treatments and innoculations for future pandemics.

He also claimed it would spark a race for raw materials that would threaten the safe and efficient production of the shots.

Instead, he said the company will provide two billion vaccine doses to low- and middle-income countries over the next 18 months.

Bourla's own pay surged to a staggering $21 million last year, a rise of 17 percent and he has scored a deal with Harper Business to write a book on the story behind the vaccine development. 


It's not just pharma companies: Amazon, Google and Facebook rake in the profits amid COVID-19 pandemic

COVID-19 helped Amazon more than triple its profits to $8.1 billion for the first quarter of 2021 with Prime memberships and third party sellers using its warehouses fueling the boom. 

In the first three months of this year, the company reported profit of $8.1billion, compared to $2.5billion for the same period the year before, according to financial results shared on Thursday.

Revenue jumped 44 per cent to $108.5billion - the second quarter in row that the company has passed the $100billion milestone.

Earnings per share came to $15.79, about $6 more per share than what Wall Street analysts expected, according to FactSet.

Net sales rose to $108.52billion in the first quarter ended March 31 from $75.45billion during the same period last year, beating analysts' average estimate of $104.47billion, according to IBES data from Refinitiv.  

News of the company's revenue, which exceeded expectations of analysts on Wall Street, sent the firm's shares surging by some 4 per cent in after-hours trading on Thursday.

Amazon is one of the few retailers that has benefited during the pandemic. As physical stores temporarily closed, people stuck at home turned to Amazon to buy groceries, cleaning supplies and more. 

That doesn't seem to be dying down, with many now branding the online shopping behemoth to basic infrastructure.

While brick-and-mortar stores closed, Amazon has now posted four consecutive record quarterly profits, attracted more than 200 million Prime loyalty subscribers, and recruited over 500,000 workers to keep up with surging consumer demand.

That has kept the world's largest online retailer at the center of workplace tumult.

Its warehouse in Bessemer, Alabama, this winter became a rallying point for organized labor, hoping staff would form Amazon's first US union and inspire similar efforts nationwide.

Workers ultimately rejected the union bid by a more than 2-to-1 margin, but CEO Jeff Bezos said the saga showed how the company had to do better for employees.

The company meanwhile has been facing litigation in New York over whether it put profit ahead of worker safety in the COVID-19 pandemic.

Amazon's operation has been unfazed by these developments.   

Bezos touted the results of the company's cloud computing unit Amazon Web Services (AWS) in a press release, saying, 'In just 15 years, AWS has become a $54billion annual sales run rate business competing against the world’s largest technology companies, and its growth is accelerating.'

Andy Jassy, who had been AWS's CEO, is scheduled to succeed Bezos as Amazon's chief this summer.

His unit continues to be a bright spot.

Just last week, for instance, Dish Network Corp announced a deal to build its 5G network on AWS. The unit increased revenue 32 per cent to $13.5billion, ahead of estimates of $13.2billion.

Adding to Amazon's revenue was its growing chain of physical stores, including Whole Foods Market and its first overseas cashier-less convenience shop, opening last month in Ealing, West London.

Amazon delved further into healthcare as well with an online doctors-visit service for employers, representing another area it is aiming to disrupt after retail, enterprise technology and Hollywood.

Profit more than tripled to $8.1billion.

Amazon, which saw its stock price nearly double in the first part of 2020 as it benefited from the pandemic, has this year underperformed the S&P 500 market index.

Its shares were up about 8.5 per cent year to date versus the index's 13 per cent gain.

At the same time, spending on COVID-19 and logistics has chipped away at Amazon's bottom line.

The company has poured money into buying cargo planes and securing new warehouses, aiming to place items closer to customers to speed up delivery.

It said Wednesday it planned to hike pay for over half a million employees, costing more than $1billion - and it is still hiring for tens of thousands more positions.

Amazon said it expects operating income for the current quarter to be between $4.5billion and $8billion, which assumes about $1.5billion of costs related to COVID-19.

While far behind ad sales leaders Facebook and Alphabet's Google, Amazon is winning business because advertisers' placements often result directly in sales, reaching customers who are on Amazon with an intention to shop.

Amazon said ad and other sales rose 77 per cent to $6.9billion, ahead of analysts' estimate of $6.2billion. 

Other tech giants also reported handsome revenue increases for the first quarter of this year.

Google's parent company Alphabet saw its revenues soar to $55.3billion in the first quarter of this year, according to a financial statement released on Tuesday - a 34 per cent increase compared to the same time last year.

The Silicon Valley company beat quarterly revenue estimates of $51.7billion, as the recovering economy and surging use of online services combined to accelerate its advertising and cloud businesses.

Apple and Facebook reported sharp increases in quarterly revenue Wednesday as both companies continue to take advantage of pandemic trends that have devastated other parts of the economy.

At Apple, revenue rose to $89.6billion - good for earnings of $1.40 a share, which beat Wall Street analysts' expectations, which called for 99 cents.

That was a 54 per cent jump in revenue from the first quarter of 2021. Sales of iPads leapt by 79 per cent, while iMac sales grew by 70 per cent, and iPhone sales rose by 65 per cent.

Profits for the quarter surged to $23.6billion, more than double the year-ago period, the company said on Wednesday.

Apple's main revenue driver continues to be the iPhone: Revenue for the iPhone rose 65 per cent to $47.9billion. That beat the expectations of Wall Street analysts, who were expecting a 42 per cent increase.

Revenue from their Macs was $9.10 billion, versus a pre-results estimate of $6.86billion.

[SAguide]

info from an Alex Berenson twitter post:

Just how big a business has #Covid become?  440 milllion PCR tests at a national average of $159 a test (probably low) equals $70 BILLION.

On PCR tests alone.  Not care.  Just tests.

from article on Medscape:
Hospitals are charging up to $650 for a simple, molecular covid test that costs $50 or less to run according to Medicare claims analyzed for KHN (not sure-  Is that Kaiser Health  ??)

[Stone]

5th exec joins Moderna billionaire club — as stock price soars despite growing number of injury reports

For the fifth time since the onset of the COVID pandemic in early 2020, the skyrocketing price of Moderna stock has produced a billionaire, but the vaccine is coming under increasing scrutiny for possible links to blood clots and heart inflammation.

June 17, 2021 (Children’s Health Defense - slightly adapted) — For the fifth time since the onset of the COVID pandemic in early 2020, the skyrocketing price of Moderna stock has produced a billionaire.

Moderna President Dr. Stephen Hoge is the company’s latest shareholder and executive to join the “three-comma-club” — with an estimated $1.1 billion fortune.

Other club members are CEO Stéphane Bancel, chairman and cofounder of Noubar Afeyan, founding investor Timothy Springer and cofounder Robert Langer, Forbes reported.

Hoge, 45, joined Moderna in 2012 and owns 0.4% of Moderna stock — worth $365 million — in addition to about $685 million in options. Like the other Moderna shareholders, Hoge frequently sells stock —  including $65.5 million worth (pre-tax) between March 2020 and April 2021.

Hoge is one of more than 40 new billionaires who made 10-figure fortunes with companies involved in the “battle against COVID.”

Activists say this wealth generation highlights the stark inequality that has resulted from the pandemic, CNN reported.

“These billionaires are the human face of the huge profits many pharmaceutical corporations are making from the monopoly they hold on these vaccines,” Anne Marriott, Oxfam’s health policy manager, said in a statement. “These vaccines were funded by public money and should be first and foremost a global public good, not a private profit opportunity.”

Since February 2020, Moderna’s share price has gained more than 700%. Over the past month alone, the company’s stock is up 29%. During this same timeframe, Moderna applied for Emergency Use Authorization from the U.S. Food and Drug Administration for its COVID vaccine in adolescents, and increased its forecasted production of vaccine in 2021, from 800 million doses to 1 billion.


Taxpayers foot the bill for vaccine research

As The Defender reported previously, Moderna’s COVID vaccine is funded almost entirely by U.S. taxpayers. Through its partnership with the U.S. government, Moderna received nearly $1 billion for research and development of its mRNA vaccine, and up to $1.525 billion for delivering 100 million doses, with an option for another 400 million.

According to Public Citizen, the National Institutes of Health (NIH) owns a 50% stake in Moderna’s mRNA vaccine, which the NIH helped develop under the National Institute of Allergy and Infectious Diseases (NIAID), run by Dr. Anthony Fauci.

As described in The People’s Vaccine, the U.S. government provided millions of dollars to Moderna as early as 2013 to help develop its mRNA technology. The NIH meanwhile was also developing new methods to target COVID spike proteins. When the new coronavirus emerged in Wuhan, China, the NIH worked with Moderna to design and test a vaccine.

The U.S. Biomedical Advanced Research Development Authority provided Moderna an additional $483 million to further develop the vaccine and scale up manufacturing.

Fauci and the NIAID have a financial incentive to push Moderna’s vaccine over competitors’ COVID vaccines — because Fauci personally, and others on staff, have a financial stake in the Moderna vaccine. Fauci and four of his hand-selected deputies will split hundreds of millions of dollars in royalties with Moderna from sales of the vaccine.

Moderna continues to ignore problems with its vaccine

Moderna’s stock has risen steadily, and its top executives have benefited accordingly, despite a growing number of reports of injuries and deaths following the vaccine.

According to the latest data from the Center for Disease Control and Prevention’s (CDC) Vaccine Adverse Events Reporting System (VAERS), between Dec. 14, 2020 and June 4, a total of 329,021 total adverse events were reported following COVID vaccines, including 5,888 deaths and 28,441 serious injury reports.

Of the 329,021 total vaccine injury reports, 152,262 were attributed to Moderna’s COVID vaccine, including 11,454 serious injuries and 2,241 reported deaths.

As The Defender reported this week, Simone Scott, a 19-year-old freshman at Northwestern University in Evanston, Ill., died June 11 of complications from a heart transplant she underwent after developing what her doctors believe was myocarditis following her second dose of the Moderna COVID vaccine.

Scott received her second dose of Moderna on May 1, after which she developed heart complications which required her to have a heart transplant. Her doctors have not fully confirmed the cause of her death, but they said it appears Scott suffered from myocarditis — which according to researchers at the National Organization for Rare Disorders, can result from infections, but “more commonly the myocarditis is a result of the body’s immune reaction to the initial heart damage.”

The Defender reported on June 15 that 21-year-old New Jersey student, Justin Harrington, suffered severe heart inflammation after receiving his second dose of Moderna’s COVID vaccine.

Justin, whose school required him to get the vaccine in order to attend classes in the fall, experienced flu-like symptoms followed by heart pain within eight to 12 hours of receiving the vaccine.

“He has to wear a heart monitor and take four different medications for six months,” Justin’s father said. “He has to sleep propped up, can’t exert himself and he’s missing out on one of the most important times of his life.”

As recently as last week, Moderna said it has not found a link between its COVID vaccine and cases of a rare heart inflammation condition reported in young people who have received the shot.

The vaccine maker said in a statement it arrived at this conclusion after “carefully reviewing available safety data to date for the Moderna COVID-19 vaccine for cases of myocarditis and/or pericarditis.”

The CDC said during a June 10 meeting of the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee the agency had identified 226 reports of heart inflammation that might meet its “working case definition” of myocarditis and pericarditis following the shots, The Defender reported last week.

According to the CDC, a total of 475 cases of myocarditis or pericarditis were recorded in patients 30 and younger who received an mRNA vaccine. The median age of people with myocarditis or pericarditis following the first dose was 30, and after the second dose, 24.

Moderna said it “will continue to closely monitor these reports and is actively working with public health and regulatory authorities to further assess this issue.”

“We clearly have an imbalance there,” said Dr. Tom Shimabukuro of the CDC’s Immunization Safety Office during the June 10 FDA meeting. The committee met to discuss safety issues surrounding the use of COVID vaccines in children as young as 6 months old.

The CDC has scheduled an emergency meeting of its advisers on June 18 to discuss higher-than-expected reports of heart inflammation following doses of Pfizer and Moderna COVID vaccines.


EU probes Moderna’s vaccine

On May 10, EU regulators called on Pfizer and Moderna to provide additional data related to the companies’ COVID vaccines and a potential link to heart inflammation, after the agency completed a safety review of all four COVID vaccines authorized for emergency use in the EU.

In a report issued May 7, PRAC disclosed its members were aware of cases of myocarditis and pericarditis following Pfizer vaccination. Regulators said they didn’t see an indication the vaccine caused these cases, but as a prevention, PRAC requested Pfizer provide further data, including an analysis of events according to age and gender in its next pandemic summary safety report and will consider if any other regulatory action is needed.

Because Moderna and Pfizer use the same mRNA technology for their vaccines, the committee asked Moderna to monitor for similar cases of heart inflammation.


mRNA vaccines also linked to blood clots

Doctors have warned both the Pfizer and Moderna vaccines also could cause blood clotting disorders, similar to those associated with the Johnson & Johnson (J&J) and AstraZeneca vaccines.

As The Defender reported in April, U.S. regulatory officials were alerted to that fact as far back as December 2020.

A study released in April by Oxford University found the number of people who developed CVST blood clots after COVID vaccines was about the same for Pfizer, Moderna and AstraZeneca, MarketWatch reported. (J&J is not approved for use in the EU, where the study originated).

A search in VAERS revealed 5,907 reports of blood clotting disorders between Dec. 14, 2020 and June 4. Of those, 2,017 reports were attributed to Moderna.